{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:05:38Z","timestamp":1785225938657,"version":"3.55.0"},"reference-count":71,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/100007299","name":"Harvard Catalyst","doi-asserted-by":"publisher","award":["5P30AG031679-10"],"award-info":[{"award-number":["5P30AG031679-10"]}],"id":[{"id":"10.13039\/100007299","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Sarcoidosis is a complex, multisystem inflammatory disease with a heterogeneous clinical spectrum. Approximately 25% of patients with systemic sarcoidosis will have cardiac involvement that portends a poorer outcome. The diagnosis, particularly of isolated cardiac sarcoidosis, can be challenging. A paucity of randomised data exist on who, when and how to treat myocardial inflammation in cardiac sarcoidosis. Despite this, corticosteroids continue to be the mainstay of therapy for the inflammatory phase, with an evolving role for steroid-sparing and biological agents. This review explores the immunopathogenesis of inflammation in sarcoidosis, current evidence-based treatment indications and commonly used immunosuppression agents. It explores a multidisciplinary treatment and monitoring approach to myocardial inflammation and outlines current gaps in our understanding of this condition, emerging research and future directions in this field.<\/jats:p>","DOI":"10.15420\/cfr.2021.16","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T12:03:30Z","timestamp":1637582610000},"source":"Crossref","is-referenced-by-count":40,"title":["Cardiac Sarcoidosis: When and How to Treat Inflammation"],"prefix":"10.15420","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7452-5526","authenticated-orcid":false,"given":"Gerard T","family":"Giblin","sequence":"first","affiliation":[{"name":"Center for Advanced Heart Disease, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7409-931X","authenticated-orcid":false,"given":"Laura","family":"Murphy","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Program and Departments of Medicine and Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-4435","authenticated-orcid":false,"given":"Garrick C","family":"Stewart","sequence":"additional","affiliation":[{"name":"Center for Advanced Heart Disease, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1443-0701","authenticated-orcid":false,"given":"Akshay S","family":"Desai","sequence":"additional","affiliation":[{"name":"Center for Advanced Heart Disease, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3119-025X","authenticated-orcid":false,"given":"Marcelo F","family":"Di Carli","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Program and Departments of Medicine and Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-6562","authenticated-orcid":false,"given":"Ron","family":"Blankstein","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Program and Departments of Medicine and Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1012-7710","authenticated-orcid":false,"given":"Michael M","family":"Givertz","sequence":"additional","affiliation":[{"name":"Center for Advanced Heart Disease, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5405-3744","authenticated-orcid":false,"given":"Usha B","family":"Tedrow","sequence":"additional","affiliation":[{"name":"Cardiac Arrhythmia Service, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School,  Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7070-0307","authenticated-orcid":false,"given":"William H","family":"Sauer","sequence":"additional","affiliation":[{"name":"Cardiac Arrhythmia Service, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School,  Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9782-2841","authenticated-orcid":false,"given":"Gary M","family":"Hunninghake","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Program, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0237-739X","authenticated-orcid":false,"given":"Paul F","family":"Dellaripa","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Program, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0598-6502","authenticated-orcid":false,"given":"Sanjay","family":"Divakaran","sequence":"additional","affiliation":[{"name":"Center for Advanced Heart Disease, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6458-5421","authenticated-orcid":false,"given":"Neal K","family":"Lakdawala","sequence":"additional","affiliation":[{"name":"Center for Advanced Heart Disease, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969\u201377. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.851352; PMID:\u00a019884472.","DOI":"10.1161\/CIRCULATIONAHA.109.851352"},{"key":"ref1","unstructured":"Hu X, Carmona EM, Yi ES, et al. Causes of death in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016;33:275\u201380. PMID:\u00a027758994."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Iwai K, Takemura T, Kitaichi M, et al. Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern. Acta Pathol Jpn 1993;43:377\u201385. https:\/\/doi.org\/10.1111\/j.1440-1827.1993.tb01149.x; PMID:\u00a08372683.","DOI":"10.1111\/j.1440-1827.1993.tb01149.x"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Yafasova A, Fosbol EL, Schou M, et al. Long-term adverse cardiac outcomes in patients with sarcoidosis. J Am Coll Cardiol 2020;76:767\u201377. https:\/\/doi.org\/10.1016\/j.jacc.2020.06.038; PMID:\u00a032792073.","DOI":"10.1016\/j.jacc.2020.06.038"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153\u201365. https:\/\/doi.org\/10.1056\/NEJMra071714; PMID:\u00a018032765.","DOI":"10.1056\/nejmra071714"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011;183:573\u201381. https:\/\/doi.org\/10.1164\/rccm.201006-0865CI; PMID:\u00a021037016.","DOI":"10.1164\/rccm.201006-0865ci"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Milburn HJ, Poulter LW, Dilmec A, et al. Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung. Clin Exp Immunol 1997;108:105\u201313. https:\/\/doi.org\/10.1046\/j.1365-2249.1997.d01-979.x; PMID:\u00a09097918.","DOI":"10.1046\/j.1365-2249.1997.d01-979.x"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Saketkoo LA, Baughman RP. Biologic therapies in the treatment of sarcoidosis. Expert Rev Clin Immunol 2016;12:817\u201325. https:\/\/doi.org\/10.1080\/1744666X.2016.1175301; PMID:\u00a027117719.","DOI":"10.1080\/1744666x.2016.1175301"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Huang H, Lu Z, Jiang C, et al. Imbalance between Th17 and regulatory T-cells in sarcoidosis. Int J Mol Sci 2013;14:21463\u201373. https:\/\/doi.org\/10.3390\/ijms141121463; PMID:\u00a024177566.","DOI":"10.3390\/ijms141121463"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Oswald-Richter KA, Richmond BW, Braun NA, et al. Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. J Immunol 2013;190:5446\u201353. https:\/\/doi.org\/10.4049\/jimmunol.1202891; PMID:\u00a023630356.","DOI":"10.4049\/jimmunol.1202891"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305\u201323. https:\/\/doi.org\/10.1016\/j.hrthm.2014.03.043; PMID:\u00a024819193.","DOI":"10.1016\/j.hrthm.2014.03.043"},{"key":"ref11","unstructured":"Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014;31:19\u201327. PMID:\u00a024751450."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Divakaran S, Stewart GC, Lakdawala NK, et al. Diagnostic accuracy of advanced imaging in cardiac sarcoidosis. Circ Cardiovasc Imaging 2019;12:e008975. https:\/\/doi.org\/10.1161\/CIRCIMAGING.118.008975; PMID:\u00a031177817.","DOI":"10.1161\/CIRCIMAGING.119.009622"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Vita T, Okada DR, Veillet-Chowdhury M, et al. Complementary value of cardiac magnetic resonance imaging and positron emission tomography\/computed tomography in the assessment of cardiac sarcoidosis. Circ Cardiovasc Imaging 2018;11:e007030. https:\/\/doi.org\/10.1161\/CIRCIMAGING.117.007030; PMID:\u00a029335272.","DOI":"10.1161\/circimaging.117.007030"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2013.09.022; PMID:\u00a024140661.","DOI":"10.1016\/j.jacc.2013.09.022"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Sperry BW, Tamarappoo BK, Oldan JD, et al. Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2018;11:336\u201345. https:\/\/doi.org\/10.1016\/j.jcmg.2017.04.020; PMID:\u00a028823747.","DOI":"10.1016\/j.jcmg.2017.04.020"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Coleman GC, Shaw PW, Balfour PC, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis. JACC Cardiovasc Imaging 2017;10:411\u201320. https:\/\/doi.org\/10.1016\/j.jcmg.2016.05.009; PMID:\u00a027450877.","DOI":"10.1016\/j.jcmg.2016.05.009"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Hulten E, Agarwal V, Cahill M, et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging 2016;9:e005001. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.005001; PMID:\u00a027621357.","DOI":"10.1161\/circimaging.116.005001"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Okada DR, Bravo PE, Vita T, et al. Isolated cardiac sarcoidosis: a focused review of an under-recognized entity. J Nucl Cardiol 2018;25:1136\u201346. https:\/\/doi.org\/10.1007\/s12350-016-0658-1; PMID:\u00a027613395.","DOI":"10.1007\/s12350-016-0658-1"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25\u00a0years in a nationwide study. Circulation 2015;131:624\u201332. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.011522; PMID:\u00a025527698.","DOI":"10.1161\/circulationaha.114.011522"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Smith ED, Lakdawala NK, Papoutsidakis N, et al. Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation 2020;141:1872\u201384. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044934; PMID:\u00a032372669.","DOI":"10.1161\/circulationaha.119.044934"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol 2016;68:411\u201321. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.605; PMID:\u00a027443438.","DOI":"10.1016\/j.jacc.2016.03.605"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging 2016;9:e003738. https:\/\/doi.org\/10.1161\/CIRCIMAGING.115.003738; PMID:\u00a026763280.","DOI":"10.1161\/circimaging.115.003738"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Ekstrom K, Lehtonen J, Nordenswan HK, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. Eur Heart J 2019;40:3121\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehz428; PMID:\u00a031230070.","DOI":"10.1093\/eurheartj\/ehz428"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Nordenswan HK, Lehtonen J, Ekstrom K, et al. Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block. Circ Arrhythm Electrophysiol 2018;11:e006145. https:\/\/doi.org\/10.1161\/CIRCEP.117.006145; PMID:\u00a030354309.","DOI":"10.1161\/circep.117.006145"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Sadek MM, Yung D, Birnie DH, et al. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol 2013;29:1034\u201341. https:\/\/doi.org\/10.1016\/j.cjca.2013.02.004; PMID:\u00a023623644.","DOI":"10.1016\/j.cjca.2013.02.004"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Orii M, Hirata K, Tanimoto T, et al . Comparison of cardiac MRI and 18F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complete heart block. Heart Rhythm 2015;12:2477\u201385. https:\/\/doi.org\/10.1016\/j.hrthm.2015.06.032; PMID:\u00a026111805.","DOI":"10.1016\/j.hrthm.2015.06.032"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Takaya Y, Kusano KF, Nakamura K, Ito H. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis. Am J Cardiol 2015;115:505\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2014.11.028; PMID:\u00a025529542.","DOI":"10.1016\/j.amjcard.2014.11.028"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006\u201310. https:\/\/doi.org\/10.1016\/s0002-9149(01)01978-6; PMID:\u00a011703997.","DOI":"10.1016\/s0002-9149(01)01978-6"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Kumar S, Barbhaiya C, Nagashima K, et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 2015;8:87\u201393. https:\/\/doi.org\/10.1161\/CIRCEP.114.002145; PMID:\u00a025527825.","DOI":"10.1161\/circep.114.002145"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Cronin EM, Bogun FM, Maury P, et al. 2019 HRS\/EHRA\/APHRS\/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm 2020;17:2\u2013154. https:\/\/doi.org\/10.1016\/j.hrthm.2019.03.002; PMID:\u00a031085023.","DOI":"10.1093\/europace\/euz202"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"McArdle BA, Birnie DH, Klein R, et al. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodeoxyglucose positron emission tomography? Circ Cardiovasc Imaging 2013;6:617\u201326. https:\/\/doi.org\/10.1161\/CIRCIMAGING.112.000289; PMID:\u00a023884290.","DOI":"10.1161\/circimaging.112.000289"},{"key":"ref32","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018;15:190\u2013252. https:\/\/doi.org\/10.1016\/j.hrthm.2017.10.035; PMID:\u00a029097320."},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Yodogawa K, Seino Y, Ohara T, et al. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol 2011;16:140\u20137. https:\/\/doi.org\/10.1111\/j.1542-474X.2011.00418.x; PMID:\u00a021496164.","DOI":"10.1111\/j.1542-474x.2011.00418.x"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Yalagudri S, Zin Thu N, Devidutta S, et al. Tailored approach for management of ventricular tachycardia in cardiac sarcoidosis. J Cardiovasc Electrophysiol 2017;28:893\u2013902. https:\/\/doi.org\/10.1111\/jce.13228; PMID:\u00a028429512.","DOI":"10.1111\/jce.13228"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005;95:143\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2004.08.083; PMID:\u00a015619415.","DOI":"10.1016\/j.amjcard.2004.08.083"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Nagai T, Nagano N, Sugano Y, et al. Effect of corticosteroid therapy on long-term clinical outcome and left ventricular function in patients with cardiac sarcoidosis. Circ J 2015;79:1593\u2013600. https:\/\/doi.org\/10.1253\/circj.CJ-14-1275; PMID:\u00a025877828.","DOI":"10.1253\/circj.cj-14-1275"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Terasaki F, Azuma A, Anzai T, et al. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis: digest version. Circ J 2019;83:2329\u201388. https:\/\/doi.org\/10.1253\/circj.CJ-19-0508; PMID:\u00a031597819.","DOI":"10.1253\/circj.CJ-19-0508"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Slivnick JA, Betz J, Kalbfleisch S, et al. High-dose intravenous glucocorticoids are effective in the acute management of ventricular arrhythmias in cardiac sarcoidosis: a case series. HeartRhythm Case Rep 2020;6:706\u201310. https:\/\/doi.org\/10.1016\/j.hrcr.2020.06.028; PMID:\u00a033101937.","DOI":"10.1016\/j.hrcr.2020.06.028"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Okabe T, Yakushiji T, Hiroe M, et al. Steroid pulse therapy was effective for cardiac sarcoidosis with ventricular tachycardia and systolic dysfunction. ESC Heart Fail 2016;3:288\u201392. https:\/\/doi.org\/10.1002\/ehf2.12095; PMID:\u00a027867531.","DOI":"10.1002\/ehf2.12095"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Fussner LA, Karlstedt E, Hodge DO, et al. Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres. Eur J Heart Fail 2018;20:1713\u201320. https:\/\/doi.org\/10.1002\/ejhf.1319; PMID:\u00a030378224.","DOI":"10.1002\/ejhf.1319"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 2013;19:545\u201361. https:\/\/doi.org\/10.1097\/MCP.0b013e3283642a7a; PMID:\u00a023880702.","DOI":"10.1097\/mcp.0b013e3283642a7a"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 2020;16:145\u201354. https:\/\/doi.org\/10.1038\/s41584-020-0373-9; PMID:\u00a032066940.","DOI":"10.1038\/s41584-020-0373-9"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010;104:717\u201323. https:\/\/doi.org\/10.1016\/j.rmed.2009.12.009; PMID:\u00a020089389.","DOI":"10.1016\/j.rmed.2009.12.009"},{"key":"ref44","unstructured":"Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:60\u20136. PMID:\u00a010746262."},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Nagai S, Yokomatsu T, Tanizawa K, et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med 2014;53:427\u201333. https:\/\/doi.org\/10.2169\/internalmedicine.53.0794; PMID:\u00a024583430.","DOI":"10.2169\/internalmedicine.53.0794"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Rosenthal DG, Parwani P, Murray TO, et al. Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis. J Am Heart Assoc 2019;8:e010952. https:\/\/doi.org\/10.1161\/JAHA.118.010952; PMID:\u00a031538835.","DOI":"10.1161\/JAHA.118.010952"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Ledingham J, Gullick N, Irving K, et al. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2017;56:2257. https:\/\/doi.org\/10.1093\/rheumatology\/kex389; PMID:\u00a029029272.","DOI":"10.1093\/rheumatology\/kex389"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Taylor PC, Balsa Criado A, Mongey AB, et al. How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient? MTX in the treat-to-target strategy. J Clin Med 2019;8:515. https:\/\/doi.org\/10.3390\/jcm8040515; PMID:\u00a030991730.","DOI":"10.3390\/jcm8040515"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086\u201393. https:\/\/doi.org\/10.1136\/ard.2008.094474; PMID:\u00a019033291.","DOI":"10.1136\/ard.2008.094474"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995;155:846\u201351. PMID:\u00a07717793.","DOI":"10.1001\/archinte.155.8.846"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008;31:1189\u201396. https:\/\/doi.org\/10.1183\/09031936.00051907; PMID:\u00a018256069.","DOI":"10.1183\/09031936.00051907"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Semin Arthritis Rheum 2017;47:288\u201394. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.005; PMID:\u00a028392046.","DOI":"10.1016\/j.semarthrit.2017.03.005"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795\u2013802. https:\/\/doi.org\/10.1164\/rccm.200603-402OC; PMID:\u00a016840744.","DOI":"10.1164\/rccm.200603-402oc"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Harper LJ, McCarthy M, Ribeiro Neto ML, et al. Infliximab for refractory cardiac sarcoidosis. Am J Cardiol 2019;124:1630\u20135. https:\/\/doi.org\/10.1016\/j.amjcard.2019.07.067; PMID:\u00a031500815.","DOI":"10.1016\/j.amjcard.2019.07.067"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Gilotra NA, Wand AL, Pillarisetty A, et al. Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience. J Card Fail 2021;27:83\u201391. https:\/\/doi.org\/10.1016\/j.cardfail.2020.08.013; PMID:\u00a032889044.","DOI":"10.1016\/j.cardfail.2020.08.013"},{"key":"ref56","unstructured":"Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014;31:91\u2013107; PMID:\u00a025078637."},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014;53:213\u201322. https:\/\/doi.org\/10.1093\/rheumatology\/ket260; PMID:\u00a023946436.","DOI":"10.1093\/rheumatology\/ket260"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Krause ML, Cooper LT, Chareonthaitawee P, Amin S. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology (Oxford) 2016;55:189\u201391. https:\/\/doi.org\/10.1093\/rheumatology\/kev309; PMID:\u00a026370399.","DOI":"10.1093\/rheumatology\/kev309"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Sweiss NJ, Lower EE, Mirsaeidi M, et al . Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 2014;43:1525\u20138. https:\/\/doi.org\/10.1183\/09031936.00224513; PMID:\u00a024488568.","DOI":"10.1183\/09031936.00224513"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133\u201340. https:\/\/doi.org\/10.1161\/01.CIR.0000077913.60364.D2; PMID:\u00a012796126.","DOI":"10.1161\/01.cir.0000077913.60364.d2"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Page RL 2nd, O\u2019Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 2016;134:e32\u201369. https:\/\/doi.org\/10.1161\/CIR.0000000000000426; PMID:\u00a027400984.","DOI":"10.1161\/cir.0000000000000426"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology (Oxford) 2019;58:e3\u201342. https:\/\/doi.org\/10.1093\/rheumatology\/key208; PMID:\u00a030137552.","DOI":"10.1093\/rheumatology\/key208"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Osborne MT, Hulten EA, Singh A, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014;21:166\u201374. https:\/\/doi.org\/10.1007\/s12350-013-9828-6; PMID:\u00a024307261.","DOI":"10.1007\/s12350-013-9828-6"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Koyanagawa K, Naya M, Aikawa T, et al. The rate of myocardial perfusion recovery after steroid therapy and its implication for cardiac events in cardiac sarcoidosis and primarily preserved left ventricular ejection fraction. J Nucl Cardiol 2021;28:1745\u201356. https:\/\/doi.org\/10.1007\/s12350-019-01916-4; PMID:\u00a031605274.","DOI":"10.1007\/s12350-019-01916-4"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol 2017;24:1741\u201358. https:\/\/doi.org\/10.1007\/s12350-017-0978-9; PMID:\u00a028770463.","DOI":"10.1007\/s12350-017-0978-9"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 2012;141:154\u201362. https:\/\/doi.org\/10.1378\/chest.11-0263; PMID:\u00a021737493.","DOI":"10.1378\/chest.11-0263"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336:1224\u201334. https:\/\/doi.org\/10.1056\/NEJM199704243361706; PMID:\u00a09110911.","DOI":"10.1056\/NEJM199704243361706"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Birnie D, Beanlands RSB, Nery P, et al. Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS-RCT). Am Heart J 2020;220:246\u201352. https:\/\/doi.org\/10.1016\/j.ahj.2019.10.003; PMID:\u00a031911261.","DOI":"10.1016\/j.ahj.2019.10.003"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385\u201397. https:\/\/doi.org\/10.1007\/s00198-007-0543-5; PMID:\u00a018292978.","DOI":"10.1007\/s00198-007-0543-5"},{"key":"ref70","unstructured":"Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1\u201326. https:\/\/doi.org\/10.1002\/art.39480; PMID:\u00a026545940."}],"container-title":["Cardiac Failure Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2021.16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T12:03:47Z","timestamp":1637582627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2021.16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":71,"URL":"https:\/\/doi.org\/10.15420\/cfr.2021.16","relation":{},"ISSN":["2057-7559","2057-7540"],"issn-type":[{"value":"2057-7559","type":"electronic"},{"value":"2057-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"article-number":"e17"}}